{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Intravenous&page=42", "query": { "intervention": "Placebo Intravenous", "page": 42 }, "page_size": 10 }, "pagination": { "page": 42, "page_size": 10, "total_count": 2347, "total_pages": 235, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Intravenous&page=43&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Intravenous&page=41&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-16T04:51:45.564Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01684163", "title": "Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Major Depressive Disorder" ], "interventions": [ { "name": "GLYX-13 5 mg/kg", "type": "DRUG" }, { "name": "GLYX-13 10 mg/kg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Naurex, Inc, an affiliate of Allergan plc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 369, "start_date": "2012-11", "completion_date": "2014-06", "has_results": false, "last_update_posted_date": "2016-03-17", "last_synced_at": "2026-10-16T04:51:45.564Z", "location_count": 26, "location_summary": "Birmingham, Alabama • Encino, California • Los Alamitos, California + 21 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Encino", "state": "California" }, { "city": "Los Alamitos", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01684163" }, { "nct_id": "NCT00316212", "title": "Study of INS50589 Intravenous Infusion in Subjects Undergoing Coronary Artery Bypass Grafting (CABG) Involving Cardiopulmonary Bypass", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Coronary Disease" ], "interventions": [ { "name": "INS50589 Intravenous Infusion", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 160, "start_date": "2006-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2016-11-18", "last_synced_at": "2026-10-16T04:51:45.564Z", "location_count": 27, "location_summary": "Birmingham, Alabama • San Diego, California • Springfield, Illinois + 13 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "San Diego", "state": "California" }, { "city": "Springfield", "state": "Illinois" }, { "city": "Springfield", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00316212" }, { "nct_id": "NCT03374800", "title": "Re-EValuating the Inhibition of Stress Erosions (REVISE) Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastrointestinal Hemorrhage (Clinically Important, Upper)" ], "interventions": [ { "name": "Placebo (0.9% saline)", "type": "DRUG" }, { "name": "Pantoprazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "McMaster University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4800, "start_date": "2018-07-09", "completion_date": "2024-01-31", "has_results": false, "last_update_posted_date": "2024-09-20", "last_synced_at": "2026-10-16T04:51:45.564Z", "location_count": 1, "location_summary": "Omaha, Nebraska", "locations": [ { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03374800" }, { "nct_id": "NCT01563445", "title": "Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII for Preventing Early Hematoma Growth in Acute Intracerebral Haemorrhage", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acquired Bleeding Disorder", "Intracerebral Haemorrhage" ], "interventions": [ { "name": "activated recombinant human factor VII", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2001-11", "completion_date": "2003-03", "has_results": false, "last_update_posted_date": "2017-01-13", "last_synced_at": "2026-10-16T04:51:45.564Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01563445" }, { "nct_id": "NCT04380636", "title": "Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lung Neoplasms", "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Placebo for olaparib", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Thoracic Radiotherapy", "type": "RADIATION" }, { "name": "Durvalumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 870, "start_date": "2020-07-06", "completion_date": "2029-07-06", "has_results": false, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-10-16T04:51:45.564Z", "location_count": 33, "location_summary": "Mobile, Alabama • Jonesboro, Arkansas • Fullerton, California + 28 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Fullerton", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04380636" }, { "nct_id": "NCT03875729", "title": "Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 1 Diabetes Mellitus" ], "interventions": [ { "name": "teplizumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Provention Bio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "8 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "8 Years to 17 Years" }, "enrollment_count": 328, "start_date": "2019-04-05", "completion_date": "2023-05-01", "has_results": true, "last_update_posted_date": "2024-04-24", "last_synced_at": "2026-10-16T04:51:45.564Z", "location_count": 34, "location_summary": "San Diego, California • San Francisco, California • Walnut Creek, California + 30 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Walnut Creek", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03875729" }, { "nct_id": "NCT05875571", "title": "Intravenous Ketorolac Administration to Attenuate Post-procedural Pain Associated With Intrauterine Device Placement", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "IUD", "Healthy Female", "Contraception", "IUD Insertion Complication" ], "interventions": [ { "name": "Ketorolac", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arkansas Children's Hospital Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "13 Years", "maximum_age": "21 Years", "sex": "FEMALE", "summary": "13 Years to 21 Years · Female only" }, "enrollment_count": 18, "start_date": "2024-02-05", "completion_date": "2025-06", "has_results": false, "last_update_posted_date": "2024-07-31", "last_synced_at": "2026-10-16T04:51:45.564Z", "location_count": 1, "location_summary": "Little Rock, Arkansas", "locations": [ { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05875571" }, { "nct_id": "NCT04410354", "title": "Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "Merimepodib", "type": "DRUG" }, { "name": "Matching Placebo", "type": "DRUG" }, { "name": "Remdesivir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViralClear Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2020-06-16", "completion_date": "2020-12-01", "has_results": false, "last_update_posted_date": "2020-12-08", "last_synced_at": "2026-10-16T04:51:45.564Z", "location_count": 10, "location_summary": "Phoenix, Arizona • Fort Lauderdale, Florida • Jacksonville, Florida + 6 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Morristown", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT04410354" }, { "nct_id": "NCT06064877", "title": "A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Head-and-neck Squamous-cell Carcinoma", "Recurrent Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "Ficlatuzumab", "type": "BIOLOGICAL" }, { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "AVEO Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 410, "start_date": "2024-01-11", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2026-04-09", "last_synced_at": "2026-10-16T04:51:45.564Z", "location_count": 28, "location_summary": "Gilbert, Arizona • Tucson, Arizona • Los Angeles, California + 23 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06064877" }, { "nct_id": "NCT00534313", "title": "Safety and Efficacy of Abatacept Versus Placebo in Participants With Psoriatic Arthritis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Psoriatic Arthritis" ], "interventions": [ { "name": "Abatacept", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 191, "start_date": "2007-11", "completion_date": "2011-05", "has_results": true, "last_update_posted_date": "2012-08-01", "last_synced_at": "2026-10-16T04:51:45.564Z", "location_count": 19, "location_summary": "Huntsville, Alabama • Palm Desert, California • Palo Alto, California + 16 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Palm Desert", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Upland", "state": "California" }, { "city": "Bridgeport", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT00534313" } ] }